Advertisement
ABIVAX SA

AAVXF News Today: Stay Updated with the Latest ABIVAX SA News in Real Time

Find AAVXF news now at Meyka AI. Stay informed with the latest ABIVAX SA stocks updates, including price news, market analysis, and expert insights.

AAVXFPNK
HealthcareBiotechnology
$101.25
$0.00(0.00%)
U.S. Market opens in 7h 19m
Advertisement
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
📅 1 day ago

GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%

GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…

Read more 12
Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns 
📅 9 days ago

Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns 

French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead…

Read more 12
Abivax Stock (EPA: ABVX) at 77.55 EUR, down 30.64% as Safety Signals Cloud Colitis Trial Results
📅 9 days ago

Abivax Stock (EPA: ABVX) at 77.55 EUR, down 30.64% as Safety Signals Cloud Colitis Trial Results

Abivax Stock came under heavy pressure on June 2, 2026, after investors focused on safety concerns linked to its ulcerative colitis drug candidate, obefazimod. The stock fell 30.64% to 77.55 EUR even though the company reported stronger-than-expected Phase 3 trial results. The sharp selloff shows that safety signals can outweigh positive efficacy data in biotechnology…

Read more 12
ABIVAX SA Climbs 2.1% as Earnings Announcement Nears on May 25
📅 20 days ago

ABIVAX SA Climbs 2.1% as Earnings Announcement Nears on May 25

ABVX.PA stock rises 2.1% to €105.1 ahead of May 25 earnings. Biotech firm faces profitability challenges with negative EPS of -4.83.

Read more 12
ABIVAX SA Stock Climbs 1.57% as Earnings Loom on May 25
📅 22 days ago

ABIVAX SA Stock Climbs 1.57% as Earnings Loom on May 25

ABVX.PA stock rises 1.57% to €97.10 ahead of May 25 earnings announcement. Biotech firm develops ABX464 for inflammatory and infectious diseases.

Read more 12
ABVX.PA ABIVAX SA (EURONEXT) -10.97% after hours 24 Mar 2026: catalysts ahead
📅 3 months ago

ABVX.PA ABIVAX SA (EURONEXT) -10.97% after hours 24 Mar 2026: catalysts ahead

ABVX.PA stock fell 10.97% after hours to EUR 97.40; analysis, Meyka AI grade and forecasts for investors.

Read more 12
€107.40 ABVX.PA stock pre-market: earnings due Mar 23 may reset targets
📅 3 months ago

€107.40 ABVX.PA stock pre-market: earnings due Mar 23 may reset targets

Pre-market look at ABVX.PA stock ahead of Mar 23 earnings; price, forecasts, Meyka grade and analyst targets

Read more 12
Eli Lilly Set to Make €15 Billion Offer for French Biotech Abivax, Report Says
📅 5 months ago

Eli Lilly Set to Make €15 Billion Offer for French Biotech Abivax, Report Says

Eli Lilly, one of the world’s biggest pharmaceutical companies, is reportedly preparing a €15 billion offer to acquire the French biotechnology firm Abivax SA, according to recent market reports. This potential deal reflects a strategic push by Eli Lilly to expand its presence in the biotech sector, tapping into cutting‑edge research and development pipelines that…

Read more 12

AAVXF News FAQ